RxDoctor Payments Data

Steven Hudson, MD

Ophthalmology · Fredericksburg, VANPI 1578554739

Payments from drug & device makers

$1,211in general payments, 2019–2025

Across 57 payments — averaging $21.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$316
  • Alcon$276
  • Sun Pharmaceutical Industries Inc.$200
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$124
  • Bausch & Lomb Americas Inc.$67
  • Novartis$53
  • plus $174 from 7 others

What the payments were for

  • Food & beverage$1,211100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,211 in reported general payments places this provider in the 50th percentile of 509 ophthalmology providers in Virginia.

See all ophthalmology providers in Virginia

Medicare billing

Part B allowed, 2024
$330,789
Medicare patients
948
Services billed
3,603

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost224$150,470
VyzultaLatanoprostene Bunod122$77,389
CombiganBrimonidine Tartrate/Timolol80$44,665
RestasisCyclosporine40$44,383
RocklatanNetarsudil Mesylat/Latanoprost56$40,216
RhopressaNetarsudil Mesylate44$34,873
Brimonidine Tartrate246$16,050
Bromfenac Sodium133$14,260
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol76$13,677
SimbrinzaBrinzolamide/Brimonidine Tart39$13,266
Alphagan PBrimonidine Tartrate18$9,724
Loteprednol Etabonate55$8,262
Travoprost48$8,166
Brinzolamide30$7,263
Prednisolone Acetate223$6,638

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Restasis, Alphagan P$316$249,242362 claims
Bausch & Lomb Americas Inc.Vyzulta$67$77,389122 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$35$75,089100 claims
AlconSimbrinza$276$13,26639 claims
Bausch & Lomb, A Division Of Bausch Health US, LLCLoteprednol Etabonate$124$8,26255 claims
NovartisIlevro$53$4,01111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 509 ophthalmology providers in Virginia.

Other ophthalmology in Fredericksburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →